

Consumer Healthcare turnover

Three months ended 30 June 2014

	Total		
	£m	CER%	AR%
Turnover			
Total wellness	366	(9)	(18)
Oral health	434	-	(10)
Nutrition	151	7	(7)
Skin health	71	(19)	(27)
Total	1,022	(4)	(14)

	Total		
	£m	CER%	AR%
Turnover			
USA	195	(11)	(18)
Europe	291	(10)	(15)
ROW	536	3	(12)
Total	1,022	(4)	(14)

Consumer Healthcare turnover

Six months ended 30 June 2014

	Total		
	£m	CER%	AR%
Turnover			
Total wellness	782	(8)	(17)
Oral health	891	2	(7)
Nutrition	321	10	(5)
Skin health	155	(11)	(20)
Total	2,149	(2)	(12)

	Total		
	£m	CER%	AR%
Turnover			
USA	397	(10)	(17)
Europe	619	(7)	(11)
ROW	1,133	4	(11)
Total	2,149	(2)	(12)

Pharmaceuticals and Vaccines turnover – Three months ended 30 June 2014

	Total			USA			Europe			Emerging Markets			Japan		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	1,559	(8)	(16)	725	(14)	(21)	437	(3)	(7)	188	(3)	(16)	95	(4)	(16)
<i>Avamys/Veramyst</i>	58	7	(3)	7	(33)	(42)	23	-	-	18	18	6	7	>100	>100
<i>Flixotide/Flovent</i>	172	(6)	(15)	106	(6)	(15)	24	(10)	(17)	13	14	(7)	7	(27)	(36)
<i>Relvar/Breo</i>	11	-	-	5	-	-	3	-	-	1	-	-	2	-	-
<i>Seretide/Advair</i>	1,095	(12)	(19)	528	(19)	(25)	348	(4)	(7)	98	(4)	(16)	45	(26)	(36)
<i>Ventolin</i>	155	8	(3)	73	14	6	30	-	(6)	40	7	(9)	1	-	(50)
Other	68	12	1	6	>100	>100	9	-	-	18	(31)	(44)	33	37	22
Oncology	295	39	27	119	42	31	106	39	33	44	47	22	15	6	(12)
<i>Arzerra</i>	12	(18)	(29)	7	(30)	(30)	5	(29)	(29)	-	-	-	-	-	-
<i>Mekinist</i>	16	-	-	15	-	-	-	-	-	-	-	-	-	-	-
<i>Promacta</i>	55	36	22	21	21	11	18	46	38	7	40	40	7	13	(13)
<i>Tafinlar</i>	33	>100	>100	14	>100	>100	16	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	45	(6)	(15)	11	(20)	(27)	18	(14)	(14)	13	45	18	1	(60)	(80)
<i>Votrient</i>	101	41	28	42	28	17	39	37	30	12	67	33	4	100	100
Other	33	(5)	(13)	9	(10)	(10)	10	22	11	12	36	9	3	50	50
Cardiovascular, metabolic and urology (CVMU)	233	(7)	(15)	90	(20)	(26)	71	(5)	(9)	35	11	-	22	(14)	(21)
<i>Avodart</i>	199	(2)	(10)	67	(13)	(20)	70	9	3	27	15	-	22	(14)	(21)
Other	34	(30)	(37)	23	(34)	(39)	1	(100)	(90)	8	-	-	-	-	-
Immuno-inflammation	42	21	11	38	17	9	3	50	50	-	-	-	-	-	-
<i>Benlysta</i>	41	21	8	37	17	6	3	50	50	-	-	-	-	-	-
Other	1	-	-	1	-	-	-	-	-	-	-	-	-	-	-
Other pharmaceuticals	596	2	(8)	29	(48)	(54)	163	3	(2)	272	5	(9)	46	(12)	(23)
Dermatology	122	(21)	(28)	11	(63)	(63)	42	(2)	(5)	59	(14)	(25)	6	(13)	(25)
<i>Augmentin</i>	147	8	(2)	(1)	-	-	43	-	(4)	97	11	(2)	2	(33)	(33)
Other anti-bacterials	53	(2)	(12)	2	-	-	13	-	(7)	39	-	(7)	1	-	-
Rare diseases	99	(13)	(22)	9	(66)	(69)	34	13	6	12	17	-	38	(8)	(21)
Other	175	36	22	8	>100	>100	31	6	(3)	65	21	(2)	(1)	<(100)	<(100)
Innovative Pharmaceuticals	2,725	(2)	(10)	1,001	(11)	(18)	780	2	(2)	539	5	(9)	178	(7)	(18)
Vaccines	766	5	(3)	192	(2)	(10)	239	(5)	(9)	283	26	15	9	(9)	(18)
<i>Boostrix</i>	94	47	38	43	12	5	26	47	37	18	>100	>100	-	-	-
<i>Cervarix</i>	22	(48)	(52)	1	(50)	(50)	10	(15)	(23)	10	(52)	(60)	-	(100)	(100)
<i>Fluarix, FluLaval</i>	6	(14)	(14)	2	(50)	-	(1)	-	-	4	-	(20)	-	-	-
Hepatitis	142	(10)	(16)	56	(16)	(23)	47	(8)	(10)	30	(6)	(17)	-	-	-
<i>Infanrix, Pediarix</i>	202	-	(7)	66	-	(8)	93	(5)	(10)	31	25	11	-	-	-
<i>Rotarix</i>	103	31	18	24	8	(4)	15	-	(6)	51	57	38	9	67	50
<i>Synflorix</i>	105	51	42	-	-	-	9	(25)	(25)	94	65	57	-	-	-
Other	92	(13)	(21)	-	-	-	40	(18)	(20)	45	(6)	(12)	-	(100)	(100)
Innovative Pharmaceuticals and Vaccines	3,491	-	(9)	1,193	(10)	(17)	1,019	-	(4)	822	11	(2)	187	(7)	(18)
ViiV Healthcare (HIV)	352	13	4	151	38	26	131	-	(4)	34	(22)	(33)	13	8	(6)
<i>Combivir</i>	16	(33)	(41)	3	(55)	(59)	5	(52)	(54)	9	(4)	(13)	-	(25)	(34)
<i>Epzicom/Kivexa</i>	188	6	(3)	67	16	6	85	7	3	15	(21)	(33)	8	(11)	(23)
<i>Lexiva/Agenerase</i>	21	(21)	(28)	11	(9)	(16)	5	(29)	(32)	3	(32)	(47)	-	(25)	(34)
<i>Selzentry</i>	38	14	9	14	(1)	(9)	16	(1)	(6)	2	71	53	-	(20)	(31)
<i>Tivicay</i>	64	-	-	48	-	-	12	-	-	-	-	-	3	-	-
<i>Trizivir</i>	7	(65)	(70)	1	(94)	(95)	6	(28)	(31)	1	(37)	(53)	-	-	-
Other	18	(38)	(44)	7	14	14	2	(75)	(83)	4	(42)	(50)	2	-	(50)
Established products	696	(24)	(32)	183	(40)	(45)	151	(10)	(14)	243	(14)	(24)	106	(21)	(31)
<i>Coreg</i>	30	(6)	(9)	29	(3)	(12)	-	-	-	-	-	-	-	-	-
<i>Hepsera</i>	21	(26)	(32)	-	-	-	-	-	-	16	(25)	(33)	4	(29)	(43)
<i>Imigran/Imitrex</i>	44	(2)	(6)	22	16	16	15	(6)	(6)	1	(50)	(50)	4	(17)	(33)
<i>Lamictal</i>	124	2	(7)	60	3	(5)	26	-	(4)	18	-	(10)	18	-	(14)
<i>Lovaza</i>	27	(81)	(83)	27	(81)	(83)	-	-	-	-	-	-	-	-	-
<i>Requip</i>	26	(3)	(10)	2	100	-	11	(15)	(15)	4	33	33	11	-	(8)
<i>Serevent</i>	26	(15)	(21)	9	(17)	(25)	13	-	(7)	1	-	-	2	(50)	(50)
<i>Seroxat/Paxil</i>	49	(29)	(38)	-	-	-	10	(27)	(33)	13	(33)	(38)	24	(27)	(35)
<i>Valtrex</i>	37	(24)	(33)	8	-	(11)	8	-	14	7	(20)	(30)	12	(50)	(57)
<i>Zeffix</i>	40	(20)	(27)	1	(75)	(75)	2	-	(33)	33	(16)	(25)	3	-	(25)
Other	272	(16)	(25)	25	(3)	(8)	66	(14)	(18)	150	(12)	(24)	28	(9)	(18)
	4,539	(4)	(12)												

The table above includes the sales by product reported in Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccines tender sales and contract manufacturing sales) in the total column only. US dollar amounts shown above are a convenience translation of the sterling amounts.

Pharmaceuticals and Vaccines turnover – Six months ended 30 June 2014

	Total			USA			Europe			Emerging Markets			Japan		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	3,113	(9)	(16)	1,404	(17)	(23)	879	(3)	(5)	374	-	(13)	243	(4)	(18)
<i>Avamys/Veramyst</i>	128	2	(9)	15	(30)	(35)	41	5	3	35	21	6	30	-	(14)
<i>Flixotide/Flovent</i>	365	(4)	(12)	229	(2)	(9)	54	(10)	(13)	25	3	(14)	14	(19)	(33)
<i>Relvar/Breo</i>	14	-	-	6	-	-	5	-	-	1	-	-	3	-	-
<i>Seretide/Advair</i>	2,134	(14)	(20)	983	(24)	(30)	700	(4)	(6)	195	-	(13)	112	-	(16)
<i>Ventolin</i>	328	11	2	165	22	14	62	(2)	(5)	78	7	(8)	3	-	(25)
Other	144	(10)	(21)	6	>100	100	17	-	-	40	(22)	(31)	81	(10)	(22)
Oncology	556	33	22	227	36	27	201	31	26	80	42	19	29	10	(6)
<i>Arzerra</i>	28	(21)	(26)	17	(10)	(15)	10	(44)	(44)	-	-	-	1	-	-
<i>Mekinist</i>	29	-	-	28	-	-	-	-	-	-	-	-	-	-	-
<i>Promacta</i>	103	33	21	39	20	11	34	46	42	12	40	20	15	29	7
<i>Tafinlar</i>	55	>100	>100	25	>100	>100	26	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	87	(10)	(17)	21	(23)	(30)	36	(12)	(14)	23	29	10	4	(44)	(56)
<i>Votrient</i>	188	36	25	79	23	14	76	39	36	21	63	31	6	75	50
Other	66	(4)	(12)	18	(25)	(25)	19	11	-	24	40	20	3	(25)	(25)
Cardiovascular, metabolic and urology (CVMU)	474	(2)	(10)	173	(19)	(25)	152	4	1	68	20	3	53	17	-
<i>Avodart</i>	398	2	(6)	126	(14)	(21)	141	9	5	53	22	4	53	17	-
Other	76	(19)	(27)	47	(30)	(34)	11	(35)	(35)	15	13	-	-	-	-
Immuno-inflammation	88	42	31	80	39	29	6	50	50	1	-	-	-	-	-
<i>Benlysta</i>	79	28	18	71	24	15	6	50	50	1	-	-	-	-	-
Other	9	-	-	9	-	-	-	-	-	-	-	-	-	-	-
Other pharmaceuticals	1,197	4	(6)	75	(38)	(42)	326	2	(2)	517	4	(10)	133	22	3
Dermatology	249	(17)	(25)	24	(60)	(62)	84	-	(2)	120	(9)	(21)	12	(7)	(20)
<i>Augmentin</i>	299	1	(8)	-	-	-	101	(3)	(6)	183	2	(9)	5	-	(17)
Other anti-bacterials	111	-	(8)	3	-	-	34	-	(3)	73	1	(9)	2	100	100
Rare diseases	205	(5)	(15)	33	(38)	(41)	67	10	6	20	10	(5)	75	(2)	(17)
Other	333	49	32	15	>100	88	40	7	(2)	121	26	3	39	>100	>100
Innovative Pharmaceuticals	5,428	(2)	(10)	1,959	(13)	(19)	1,564	2	(1)	1,040	6	(8)	458	6	(10)
Vaccines	1,424	4	(3)	364	9	1	479	(1)	(4)	473	10	-	14	(27)	(36)
<i>Boostrix</i>	154	45	35	73	26	18	41	34	28	28	>100	>100	-	-	-
<i>Cervarix</i>	56	(28)	(35)	2	(33)	(33)	25	(7)	(11)	29	(19)	(31)	-	(100)	(100)
<i>Fluarix, FluLaval</i>	15	(23)	(32)	2	(67)	(67)	(1)	50	50	10	(14)	(29)	-	-	-
Hepatitis	262	(9)	(15)	100	(15)	(21)	93	(3)	(5)	49	(8)	(18)	-	-	-
<i>Infanrix, Pediarix</i>	404	9	2	137	35	25	185	(4)	(7)	54	9	(4)	-	-	-
<i>Rotarix</i>	189	24	13	50	4	(4)	33	26	22	85	40	25	14	45	27
<i>Synflorix</i>	167	7	2	-	-	-	21	(8)	(13)	143	9	4	-	-	-
Other	177	(9)	(15)	-	-	-	82	(11)	(14)	75	(6)	(13)	-	-	-
Innovative Pharmaceuticals and Vaccines	6,852	(1)	(9)	2,323	(10)	(16)	2,043	1	(2)	1,513	7	(6)	472	5	(11)
ViiV Healthcare (HIV)	663	9	1	273	20	11	256	(1)	(4)	64	(6)	(20)	26	17	-
<i>Combivir</i>	32	(42)	(47)	6	(63)	(66)	11	(55)	(56)	14	(5)	(15)	1	(11)	(25)
<i>Epzicom/Kivexa</i>	365	9	1	126	9	2	167	7	4	30	(1)	(16)	17	14	(3)
<i>Lexiva/Agenerase</i>	43	(16)	(23)	22	(18)	(24)	11	(24)	(26)	7	8	(13)	1	(13)	(26)
<i>Selzentry</i>	71	4	(1)	26	(3)	(10)	31	-	(3)	3	8	(8)	1	(12)	(25)
<i>Tivicay</i>	95	-	-	74	-	-	16	-	-	-	-	-	3	-	-
<i>Trizivir</i>	18	(60)	(62)	4	(84)	(85)	12	(27)	(29)	1	4	(17)	-	-	-
Other	39	(30)	(35)	15	(10)	(25)	8	(61)	(56)	9	(29)	(36)	3	-	(25)
Established products	1,510	(18)	(25)	439	(29)	(33)	318	(12)	(14)	507	(11)	(20)	222	(12)	(25)
<i>Coreg</i>	62	-	(6)	61	2	(6)	-	-	-	-	-	-	-	-	-
<i>Hepsera</i>	44	(17)	(24)	-	-	-	-	-	-	33	(20)	(27)	10	(8)	(23)
<i>Imigran/Imitrex</i>	90	-	(5)	46	15	12	30	(6)	(9)	3	(25)	(25)	8	(17)	(33)
<i>Lamictal</i>	250	3	(6)	116	(4)	(10)	54	-	(2)	36	5	(8)	40	23	3
<i>Lovaza</i>	132	(54)	(57)	131	(54)	(57)	-	-	-	-	-	-	-	-	-
<i>Requip</i>	54	-	(10)	4	67	33	22	(21)	(21)	7	14	-	22	18	-
<i>Serevent</i>	53	(14)	(20)	18	(20)	(28)	26	(4)	(7)	2	-	-	5	(29)	(29)
<i>Seroxat/Paxil</i>	104	(22)	(32)	-	-	-	22	(21)	(24)	30	(25)	(32)	49	(16)	(29)
<i>Valtrex</i>	74	(24)	(33)	14	(20)	(30)	15	7	7	16	-	(16)	26	(43)	(52)
<i>Zeffix</i>	85	(18)	(24)	2	(71)	(71)	4	(17)	(33)	71	(15)	(22)	6	-	(25)
Other	562	(14)	(23)	47	(20)	(24)	145	(16)	(19)	309	(9)	(19)	56	(13)	(22)
	9,025	(4)	(11)												

The table above includes the sales by product reported in Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccines tender sales and contract manufacturing sales) in the total column only. US dollar amounts shown above are a convenience translation of the sterling amounts.